Articles tagged "Immunosuppression"

2022 American Transplant Congress
An Interim Report on a Prospective Randomized Trial of Extended-Release Tacrolimus in Liver Transplantation with Anti-Thymocyte Induction in a Steroid Free Protocol
R. A. Helmick, S. Naik, C. Eymard, J. Eason, J. Vanatta
James D. Eason Transplant Institute at Methodist University Hospital and University of Tennessee Health Science Center, Memphis, TN
*Purpose: Our study hypothesis was that once daily dosing of extended-release tacrolimus (ERT) would be a safe and effective immunosuppression (IS) with the potential to…
2022 American Transplant Congress
Comparing Infection Rate Between Steroid Withdrawal and Ongoing Maintenance Among Simultaneous Pancreas-Kidney Transplant Recipients
M. McCord¹, Z. Yetmar², A. Lemke¹, K. Mara³, M. T. Seville⁴, W. Bosch⁵, P. Dean⁶, E. Beam², S. Bernard¹
¹Department of Pharmacy, Mayo Clinic, Rochester, MN, ²Division of Infectious Diseases, Mayo Clinic, Rochester, MN, ³Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, ⁴Division of Infectious Diseases, Mayo Clinic Arizona, Scottsdale, AZ, ⁵Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL, ⁶Division of Transplantation Surgery, Mayo Clinic, Rochester, MN
*Purpose: Compare infection rates of simultaneous pancreas-kidney transplant (SPK) recipients who continue maintenance steroids to those with steroid withdrawal post transplant.*Methods: This study is a…
2022 American Transplant Congress
Early Tacrolimus Exposure is Associated with BK-Viremia in Kidney Transplant Recipients
S. Meziyerh, A. L. van Rijn, D. van der Helm, P. J. van der Boog, T. van Gelder, A. C. Kroes, J. W. de Fijter, D. J. Moes, J. I. Rotmans, M. C. Feltkamp, A. P. de Vries
LUMC, Leiden, Netherlands
*Purpose: There is scant evidence to what extent maintenance immunosuppression is quantitatively associated with BK viremia. We investigated the association between tacrolimus (tac) whole blood…
2022 American Transplant Congress
Alemtuzumab and Basilximab Induction Therapy in Lung Transplantation
M. Furukawa, E. Chan, P. G. Sanchez
Cardiothoracic Surgery, UPMC, Pittsburgh, PA
*Purpose: Induction therapy is used in about more than 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guideline…
2022 American Transplant Congress
CD209+ Macrophages-Mediated Immunosuppressive Effects in ADPKD Tissues
Z. Ou¹, Y. Wang¹, Z. Yan¹, Y. Liu¹, Q. Li¹, Y. Fang¹, J. Geng¹, W. Deng¹, Z. Li¹, R. Xia¹, W. Zeng¹, J. Xu¹, C. Wu², Y. Miao¹
¹Nanfang Hospital, Guangzhou, China, ²Departments of Urology and Pathology, Massachusetts General Hospital, Boston, MA
*Purpose: The intensity of maintenance immunosuppression required in autosomal dominant polycystic kidney disease (ADPKD) patients after renal transplantation is lower than average, suggesting a reduced…
2022 American Transplant Congress
A Cost Effectiveness Analysis of Adherence Promotion Strategies to Improve Rejection Rates in Adolescent Kidney Transplant Patients
C. Varnell¹, K. Rich¹, A. Modi¹, D. Hooper¹, M. Eckman²
¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²University of Cincinnati School of Medicine, Cincinnati, OH
*Purpose: In adolescents with a kidney transplant, non-adherence increases the risk of graft loss. Adherence promotion interventions improve adherence and rejection rates, but perceived cost…
2022 American Transplant Congress
Donor-Derived Cell-Free DNA (dd-cfDNA) for Assessment of Response After Treatment of Allograft Rejection
R. Gohh¹, J. Klein², M. Jagadeesan³, V. Rao⁴, M. Weir⁵, H. Gilligan⁶, G. Shekhtman⁷, N. Agrawal⁸, Y. Fu⁹, E. Akalin¹⁰
¹Alpert School of Medicine, Brown University, Providence, RI, ²University of Kansas Medical Center, Kansas City, KS, ³George Washington School of Medicine, Washington, DC, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Maryland, Baltimore, MD, ⁶Massachusetts General Hospital, Boston, MA, ⁷CareDx Inc., Brisbane, CA, ⁸CareDx Inc, Brisbane, CA, ⁹CareDx, Brisbane, CA, ¹⁰Montefiore Medical Center, Bronx, NY
*Purpose: Surveillance of dd-cfDNA after therapy for rejection represents a promising strategy for monitoring post-treatment response. We assessed post-rejection kinetics of dd-cfDNA among kidney transplant…
2022 American Transplant Congress
Effectiveness and Limitations of PK Analysis in Optimization of Immunosuppressive Therapy for Kidney Transplantation
M. Okumura, K. Ishiyama, S. Ashimine, Y. Miwa, K. Iwasaki, T. Kobayashi
Division of Kidney Transplantation, Department of Surgery, Aichi Medical University, Nagakute, Japan
*Purpose: In recent years, significant improvement in organ transplant outcomes have been achieved by using multidrug therapy with several immune monitoring, but the complexity of…
2022 American Transplant Congress
Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial
Z. Al Fatly¹, M. G. Betjes¹, A. L. Messchendorp², J. S. Sanders², M. E. Reinders¹, M. M. Kho¹, A. E. de Weerd¹
¹Department of Internal Medicine, Erasmus MC Transplant Institute University Medical Center, Rotterdam, Netherlands, ²Department of Internal Medicine, Groningen Medical Center, Groningen, Netherlands
*Purpose: To investigate the effect of mycophenolate mofetil (MMF) on SARS-CoV-2 vaccination response in kidney transplant recipients using the standard immunosuppressive regimen of tacrolimus (TAC)…
2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
R. W. Lincoln¹, K. Kalvakuri², A. Guha², A. Bhimaraj², E. E. Suarez², A. Saharia³, C. M. Mobley³, F. Amirkhosravi³, J. Krisl¹
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, ³Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…